Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data ? Randomization to be Completed in Phase II Part in Q4 2025

globenewswire

Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data ? Randomization to be Completed in Phase II Part in Q4 2025 – NEWSnet – News… as it used to be

More Press Releases

April 30, 2026

The Pet Lovers’ Choice Awards Launches ‘Best in State’ Awards and USA TODAY Pets to Present ‘Best Pet in the Nation’ Award

April 30, 2026

WidePoint Sets First Quarter 2026 Conference Call for Thursday, May 14, 2026, at 4:30 p.m. ET

April 30, 2026

Arteris Wins Stevie Award for Technology Innovation of the Year

April 30, 2026

Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data ? Randomization to be Completed in Phase II Part in Q4 2025

The Pet Lovers’ Choice Awards Launches ‘Best in State’ Awards and USA TODAY Pets to Present ‘Best Pet in the Nation’ Award

WidePoint Sets First Quarter 2026 Conference Call for Thursday, May 14, 2026, at 4:30 p.m. ET

Arteris Wins Stevie Award for Technology Innovation of the Year

Encore Technologies Expands Partnership with Greenfoot Energy Solutions to Advance HYGN Retrofit Applications Across Industrial Markets